These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25208882)

  • 1. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
    Mattoo AR; Zhang J; Espinoza LA; Jessup JM
    Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
    Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
    Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
    Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
    Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
    Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3β signaling.
    Yu Z; Du J; Zhao Y; Gao Y; Li Y; Zhao K; Lu N
    Cancer Lett; 2021 Feb; 498():31-41. PubMed ID: 33129955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
    Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
    Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.
    Meynet O; Zunino B; Happo L; Pradelli LA; Chiche J; Jacquin MA; Mondragón L; Tanti JF; Taillan B; Garnier G; Reverso-Meinietti J; Mounier N; Michiels JF; Michalak EM; Carles M; Scott CL; Ricci JE
    Blood; 2013 Oct; 122(14):2402-11. PubMed ID: 23966420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
    Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
    Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.